RxDoctor Payments Data

Scott Shindler, DPM

Podiatrist · Wausa, NENPI 1295742310

Payments from drug & device makers

What this record shows

34 manufacturers reported payments, led by Triad Life Sciences Inc. at 48.9% of the total. Reporting peaked in 2022 at $4,504 and has fallen 78.8% since, to $955 in 2025.

$7,951in general payments, 2019–2025

Across 166 payments — averaging $47.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Triad Life Sciences Inc.$4K
  • AbbVie$844
  • Paratek Pharmaceuticals, Inc.$580
  • Amgen$524
  • Kerecis Limited$384
  • Electronic Waveform Lab, Inc.$307
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$3,77347%
  • Food & beverage$4,17853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,951 in reported general payments places this provider in the 80th percentile of 29 podiatrist providers in Nebraska.

See all podiatrist providers in Nebraska

Medicare billing

Part B allowed, 2024
$142,057
Medicare patients
82
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib11$318
Terbinafine Hcl11$273
Cephalexin21$215
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$168

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wausa

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →